PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

被引：527

作者：

Glaviano, Antonino ^{[1
]}

Foo, Aaron S. C. ^{[2
]}

Lam, Hiu Y. ^{[3
,4
]}

Yap, Kenneth C. H. ^{[3
,4
]}

Jacot, William ^{[5
]}

Jones, Robert H. ^{[6
,7
]}

Eng, Huiyan ^{[2
,3
]}

Nair, Madhumathy G. ^{[8
]}

Makvandi, Pooyan ^{[9
]}

Geoerger, Birgit ^{[10
]}

Kulke, Matthew H. ^{[11
,12
]}

Baird, Richard D. ^{[13
]}

Prabhu, Jyothi S. ^{[8
]}

Carbone, Daniela ^{[1
]}

Pecoraro, Camilla ^{[1
]}

Teh, Daniel B. L. ^{[14
,15
,16
]}

Sethi, Gautam ^{[2
,3
]}

Cavalieri, Vincenzo ^{[1
]}

Lin, Kevin H. ^{[17
]}

Javidi-Sharifi, Nathalie R. ^{[17
]}

Toska, Eneda ^{[18
]}

Davids, Matthew S. ^{[17
]}

Brown, Jennifer R. ^{[17
]}

Diana, Patrizia ^{[1
]}

Stebbing, Justin ^{[19
]}

Fruman, David A. ^{[20
]}

Kumar, Alan P. ^{[2
,3
]}

机构：

[1] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol, I-90123 Palermo, Italy

[2] Natl Univ Singapore, Natl Univ Singapore Hosp, Dept Surg, Singapore, Singapore

[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore

[4] Natl Univ Singapore, Yong Loo Lin Sch Med, NUS Ctr Canc Res N2CR, Singapore 119077, Singapore

[5] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Inserm U1194, Montpellier, France

[6] Cardiff Univ, Museum Ave, Cardiff CF10 3AX, Wales

[7] Velindre Canc Ctr, Museum Ave, Cardiff CF10 3AX, Wales

[8] St Johns Res Inst, Div Mol Med, St Johns Med Coll, Bangalore 560034, Karnataka, India

[9] Wenzhou Med Univ, Quzhou Peoples Hosp, Quzhou Affiliated Hosp, Quzhou 324000, Zhejiang, Peoples R China

[10] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Inserm U1015, Paris, France

[11] Boston Univ, Sect Hematol & Med Oncol, Boston, MA USA

[12] Boston Med Ctr, Boston, MA USA

[13] Canc Res UK Cambridge Ctr, Hills Rd, Cambridge CB2 0QQ, England

[14] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore

[15] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore

[16] Natl Univ Singapore, Neurobiol Programme, Singapore, Singapore

[17] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[18] Johns Hopkins Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD USA

[19] Imperial Coll London, Div Canc, Hammersmith Campus,Cane Rd, London W12 0NN, England

[20] Univ Calif Irvine, Dept Mol Biol & Biochem, 216 Sprague Hall, Irvine, CA USA

来源：

MOLECULAR CANCER | 2023年 / 22卷 / 01期

关键词：

PI3K; AKT; mTORC pathway; Pan PI3K inhibitors; Isoform-specific PI3K inhibitors; Dual PI3K; mTOR inhibitors; AKT inhibitors; Allosteric mTOR inhibitors; ATP-competitive mTOR inhibitors; Bi-steric mTOR inhibitors; PDK1; inhibitors; Cancer; RENAL-CELL CARCINOMA; FOXO TRANSCRIPTION FACTORS; ADVANCED BREAST-CANCER; PHASE-I TRIAL; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; NONFUNCTIONAL NEUROENDOCRINE TUMORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INTRAVENOUS PI3K INHIBITOR; PROTEIN-COUPLED RECEPTORS; HEPATOCYTE GROWTH-FACTOR;

D O I：

10.1186/s12943-023-01827-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.

引用

页数：37

共 50 条

[41] PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Zhu, Kunrui
Wu, Yanqi
He, Ping
Fan, Yu
Zhong, Xiaorong
Zheng, Hong
Luo, Ting
CELLS, 2022, 11 (16)
[42] PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression
Fath, Mohsen Karami
Masouleh, Ramtin Akhavan
Afifi, Negin
Loghmani, Shirin
Tamimi, Parham
Fazeli, Alireza
Mousavian, Seyed Ali
Falsafi, Mohammad Mehdi
Barati, Ghasem
PATHOLOGY RESEARCH AND PRACTICE, 2023, 241
[43] Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
Ediriweera, Meran Keshawa
Tennekoon, Kamani Hemamala
Samarakoon, Sameera Ranganath
SEMINARS IN CANCER BIOLOGY, 2019, 59 : 147 - 160
[44] Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Wilks, Sharon T.
BREAST, 2015, 24 (05): : 548 - 555
[45] LHPP suppresses gastric cancer progression via the PI3K/AKT/mTOR signaling pathway
Wang, Danfang
Li, Jianhui
Li, Wenhan
JOURNAL OF CANCER, 2022, 13 (14): : 3584 - 3592
[46] The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
Mardanshahi, Alireza
Gharibkandi, Nasrin Abbasi
Vaseghi, Samaneh
Abedi, Seyed Mohammad
Molavipordanjani, Sajjad
MOLECULAR BIOLOGY REPORTS, 2021, 48 (08) : 6167 - 6180
[47] Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
Johnson, Sara M.
Gulhati, Pat
Rampy, Bill A.
Han, Yimei
Rychahou, Piotr G.
Doan, Hung Q.
Weiss, Heidi L.
Evers, B. Mark
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (05) : 767 - 776
[48] The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
Alireza Mardanshahi
Nasrin Abbasi Gharibkandi
Samaneh Vaseghi
Seyed Mohammad Abedi
Sajjad Molavipordanjani
Molecular Biology Reports, 2021, 48 : 1 - 14
[49] Exploring the roles of ncRNAs in prostate cancer via the PI3K/AKT/mTOR signaling pathway
Guo, Rongwang
Shi, Liji
Chen, Yonghui
Lin, Canling
Yin, Weihua
FRONTIERS IN IMMUNOLOGY, 2025, 16
[50] Involvement of PI3K/Akt pathway in prostate cancer -: Potential strategies for developing targeted therapies
Pommery, N
Hénichart, JP
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (12) : 1125 - 1132

← 1 2 3 4 5 →